Edition 25 – Substance Use
Edition 25, Substance Use
According to the World Health Organization, more than 42 million years of healthy life loss were attributable to drug use in 2017; about 1.3% of the global burden of disease.
The articles in this edition contextualize the origins, challenges, and potential approaches to addressing the opioid crisis in working towards its resolution. From understanding the mindset behind why choices are made and the social conditions leading up to them, to the adverse consequences of self-medication, to escaping addiction cycles, and the discussion of care models centering around applying patient centered care practices to address these challenges, the HPHR is working towards bringing these issues to the forefront for discourse in hopes of change.
~ Catherine Tsasis, Junior Associate Editor, HPHR
Edition 25 – “The War on Drugs”: The Case of Bangladesh
•
May 27, 2021
“The War on Drugs”: The Case of Bangladesh By Nazrul Islam Share on facebook Facebook Share on twitter Twitter Share on linkedin
Edition 25 – Buprenorphine Prior Authorization Removal: Low Hanging Fruit in the Opioid Overdose Crisis
•
May 27, 2021
Buprenorphine Prior Authorization Removal: Low Hanging Fruit in the Opioid Overdose Crisis By Tamara Beetham Share on facebook Facebook Share on twitter
Edition 25 – Tackling the Opioid Epidemic: Using the Enhanced Recovery After Surgery Principles to Manage Gynecological Post-Op Pain
•
May 27, 2021
Tackling the Opioid Epidemic: Using the Enhanced Recovery After Surgery Principles to Manage Gynecological Post-Op Pain By Kimia Etemadi Share on facebook
Edition 25 – Intergenerational Effects of Alcoholism, Children of Sober Alcoholics: Brain and Behavioral Risks, Interventions, and Implications
•
May 27, 2021
Intergenerational Effects of Alcoholism, Children of Sober Alcoholics: Brain and Behavioral Risks, Interventions, and Implications By Julia Benville Share on facebook Facebook
Edition 25 – Purdue Pharma and OxyContin – A Commercial Success But Public Health Disaster
•
May 25, 2021
Purdue Pharma and OxyContin – A Commercial Success But a Public Health Disaster By Ronald Chow Share on facebook Facebook Share on